Last month 86 different plaintiffs filed a lawsuit in the U.S. District Court for the Northern District of California against Gilead Sciences alleging side effects of tenofovir disoproxil fumarate (TDF) infused HIV drugs like Truvada, Stribild and other medications.
According to the lawsuit filed, the plaintiffs claimed that they could have evaded the unreasonably dangerous risk of kidney problems, bone fractures, and other injuries if the manufacturer had issued safer alternatives that contained different antiviral, which was available years earlier. The lawsuit further states Gilead knew that a less toxic version of the drugs could be developed, involving the antiviral tenofovir alafenamide fumarate (TAF), yet withheld it for years and continued the sale of the more toxic versions until patent protections expired and generic equivalents were introduced.
The lawsuit is now a part of an increasing number of complaints filed by plaintiffs nationwide, who have made similar allegations against the manufacturer. The complaints are currently pending in California state court, but a growing number have also been filed in various federal district courts nationwide over the past year.
